Your browser doesn't support javascript.
loading
Fast and robust protocol for prenatal diagnosis of mucopolysaccharidosis type II
Brusius-Facchin, Ana Carolina; Gus, Rejane; Burin, Maira; Sanseverino, Maria Teresa; Magalhães, José Antônio; Giuglian, Roberto; Leistner-Sega, Sandra.
  • Brusius-Facchin, Ana Carolina; Hospital de Clinicas de Porto Alegre. Serviço de Genética Médica. Porto Alegre. BR
  • Gus, Rejane; Hospital de Clinicas de Porto Alegre. Serviço de Genética Médica. Porto Alegre. BR
  • Burin, Maira; Hospital de Clinicas de Porto Alegre. Serviço de Genética Médica. Porto Alegre. BR
  • Sanseverino, Maria Teresa; Hospital de Clinicas de Porto Alegre. Serviço de Genética Médica. Porto Alegre. BR
  • Magalhães, José Antônio; Hospital de Clínicas de Porto Alegre. Serviço de Ginecologia e Obstetrícia. Porto Alegre. BR
  • Giuglian, Roberto; Hospital de Clinicas de Porto Alegre. Serviço de Genética Médica. Porto Alegre. BR
  • Leistner-Sega, Sandra; Hospital de Clínicas de Porto Alegre. Serviço de Genética Médica. Porto Alegre. BR
Clin. biomed. res ; 34(4): 371-373, 2014. tab
Article in English | LILACS | ID: biblio-834481
ABSTRACT
Introduction: Mucopolysaccharidosis type II (MPSII) is an X-linked lysosomal disorder caused by deficiency of iduronate-2-sulfatase (IDS). In this study, we proposed a new protocol for prenatal diagnosis, using DNA obtained from amniotic fluid cells that did not attach to the bottom of the culture flask after the first medium change. Methods: Four pregnant MPS II carriers were referred to the Medical Genetics Service of Hospital de Clinicas de Porto Alegre for a prenatal diagnosis and identification of the disease, which were performed by polymerase chain reaction (PCR) amplification, restriction fragment length polymorphism, and sequencing according to the mutation previously found in the family. Results: The analysis indicated the absence of mutation in three fetal materials and the presence of mutation in one case. Concomitantly, cytogenetic and biochemical analyses were performed after 12 days of cell culture, and only one case showed absence of enzyme activity, confirming the molecular analysis. Conclusions: This diagnostic protocol designed to provide more robust results and safer genetic counseling suggests that DNA obtained from floating amniotic fluid cells can be used as a source of fetal material to allow a faster alternative for prenatal care through molecular analysis. Determination of IDS gene mutation in fetal amniotic fluid cells together with IDS enzyme activity testing is a rapid, sensitive and accurate method for prenatal diagnosis of MPS II for high-risk pregnant women.
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Prenatal Diagnosis / DNA Mutational Analysis / Mucopolysaccharidosis II / Pathology, Molecular / Fetal Diseases / Fetus Type of study: Diagnostic study / Practice guideline / Prognostic study Limits: Female / Humans / Male / Pregnancy Language: English Journal: Clin. biomed. res Journal subject: Medicine Year: 2014 Type: Article Affiliation country: Brazil Institution/Affiliation country: Hospital de Clinicas de Porto Alegre/BR / Hospital de Clínicas de Porto Alegre/BR

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Prenatal Diagnosis / DNA Mutational Analysis / Mucopolysaccharidosis II / Pathology, Molecular / Fetal Diseases / Fetus Type of study: Diagnostic study / Practice guideline / Prognostic study Limits: Female / Humans / Male / Pregnancy Language: English Journal: Clin. biomed. res Journal subject: Medicine Year: 2014 Type: Article Affiliation country: Brazil Institution/Affiliation country: Hospital de Clinicas de Porto Alegre/BR / Hospital de Clínicas de Porto Alegre/BR